Factors associated with resolution of type-2 diabetes mellitus after sleeve gastrectomy in obese adults

Comparison of SADI-S Versus SG in Chinese with Diabetes and BMI < 35 kg/m2:a Retrospective Study with Medium-Term Outcomes

BACKGROUND

As a modification of the duodenal switch (DS), the single-anastomotic ileo-ileal bypass combined with sleeve gastrectomy (SADI-S) has recently gained popularity and has been successfully employed for weight loss and the remission of type 2 diabetes mellitus (T2DM). However, current studies predominantly focus on patients with severe obesity.

OBJECTIVES

In this study, we present the first comparison of single-anastomotic duodenoileal bypass combined with sleeve gastrectomy (SADI-S) and sleeve gastrectomy (SG) for the mid-term treatment of Chinese diabetic patients with a BMI < 35 kg/m2. This research provides comparative reports on the efficacy of these two surgical approaches.

PATIENTS AND METHODS

We included 53 diabetic patients with BMI < 35 kg/m2 who underwent either SADI-S or SG and were followed for 2 years postoperatively. Demographic characteristics, weight loss, and nutritional and metabolic outcomes were analyzed at 3-month, 6-month, 1-year, and 2-year follow-up intervals. All surgeries were performed by the same surgeon at a single weight loss center in China between July 2015 and November 2022.

RESULTS

A total of 24 patients who underwent Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy (SADI-S) and 29 patients who underwent Sleeve Gastrectomy (SG) were included in our analysis. Comparative analysis of the baseline indicators between the two groups revealed no statistically significant differences (P > 0.05).Both patient groups completed a 2-year follow-up. In terms of weight loss, the SADI-S group demonstrated superior outcomes compared to the SG group, with better results in weight, BMI, and total weight loss percentage (%TWL) at the 2-year follow-up, and these differences were statistically significant (66.9 ± 7.9 vs. 61.2 ± 6.6, p = 0.007; 23.8 ± 2.0 vs. 21.7 ± 1.6, p = 0.000; 31.1% ± 6.3% vs. 24.4% ± 6.4%, p = 0.000). Regarding diabetes remission, the SADI-S group also outperformed the SG group (p = 0.000). Specifically, 91.8% of patients in the SADI-S group achieved complete remission of T2DM, compared to 41.4% in the SG group (p = 0.000). Furthermore, the SADI-S group showed significantly better results in the remission of hyperlipidemia compared to the SG group.However, there was no significant difference in hypertension relief between the SADI-S group and the SG group. Additionally, the incidence of postoperative hypozincemia was significantly higher in the SADI-S group compared to the SG group (p = 0.038). No significant differences were observed in other postoperative nutritional outcomes between the two groups.

CONCLUSION

In Chinese diabetic patients with a BMI < 35 kg/m2, both SADI-S and SG were effective in treating obese T2DM.However, compared with SG, primary SADI-S can achieve better weight loss and remission of obesity-related metabolic diseases.Additionally, the rates of postoperative nutritional deficiencies were found to be acceptable. Nonetheless, multicenter studies with larger sample sizes and longer follow-up periods are necessary to draw definitive conclusions.

The role of gut microbiota in predicting the weight loss following laparoscopic sleeve gastrectomy

Background

Laparoscopic sleeve gastrectomy (LSG) has emerged as a highly effective intervention in the management of obesity. While there has been a recent surge in research exploring the relationship between obesity and gut microbiota, the association between gut microbiota and LSG remains relatively underexplored. This study aimed to investigate the relationship between gut microbiota and both early and later effects of LSG.

Methods

In this retrospective study, clinical characteristics and preoperative fecal samples were collected from 52 individuals who underwent LSG. Using 16S rRNA gene sequencing, we compared the community composition, alpha diversity, and beta diversity of gut microbiota between patients who experienced efficient weight loss and those who did not. Additionally, comprehensive and correlation analyses were performed to identify potential associations between specific microbial taxa and LSG outcomes.

Results

The abundances of gut microbiota in patients who experienced efficient weight loss and those who experienced general weight loss were comparable. However, the influence of gut microbiota on the efficacy of weight loss is dynamic. Specifically, the Fusobacteriota phylum significantly contributed to the early curative effects of LSG, while Actinobacteriota had a greater impact on the late curative effects. Additionally, Proteobacteria were found to mediate long-term efficacy through complex mechanisms.

Conclusion

This study analyzed the preoperative gut microbiota signature to predict the efficacy of LSG, potentially offering valuable insights for clinical applications. Preoperative assessment of gut microbiota profiles could assist patients in their decision-making processes, particularly regarding the potential outcomes of LSG and the long-term impact of the procedure on their health.

Surgical Strategies for the Management of Obesity

Obesity is one of the most difficult medical conditions to treat in the United States (US) and requires multidisciplinary treatment. Bariatric surgery is one of the most effective treatment options for morbid obesity. In this review, we describe the most up-to-date information regarding the impact of obesity on cardiovascular disease and other comorbidities as well as the various surgical approaches for treatment.

Short-term impact of bariatric surgery on the dietary intake of patients with type 2 diabetes

BACKGROUND

The prevalence of overweight and obesity and an unhealthy diet and lifestyle are the key causes of rising diabetes burden in India. Bariatric surgery is gaining popularity in India as a favored approach to manage obesity and its accompanying comorbidities. Despite this, there is a scarcity of Indian studies evaluating dietary intake. Our goal was to analyse the dietary intake of Indian patients with type 2 diabetes mellitus (T2DM) who have undergone laparoscopic sleeve gastrectomy (LSG) or duodeno-jejunal bypass with sleeve gastrectomy (DJB-SG) or surgeries.

METHODS

The longitudinal observational study included 64 T2DM patients (32 in each procedure) enrolled through purposive sampling. The patients underwent surgery (LSG or DJB-SG procedure) between January 2017 and July 2019. Dietary data was collected at baseline and postsurgery (12 months) using a 24-h dietary recall method for 2 days (one working and one holiday).

RESULTS

The total sample consisted of 27 (42.2%) females and 37 (57.8%) males. The mean age was 46.8 years. At 12 months, the follow-up for the LSG and DJB-SG procedures was 100% and 78%, respectively. In the short term, a significant reduction was seen in weight, body mass index and haemoglobin A1C (HbA1C) in both surgical groups. The two procedures were comparable with respect to weight loss but improvement in glycaemia was higher in the DJB-SG group. The dietary intake (food groups and nutrients) was similar in the two surgical groups at baseline and 12 months postsurgery. Dietary intake assessment showed significant reduction in calorie dense foods (cereals, roots and tubers, fats and oils, table sugar, and biscuits) in both surgical groups. Among nutrients, intake of energy, fats, carbohydrates, dietary fibre, thiamine, riboflavin, niacin, folate and iron were reduced significantly in both procedures. Vitamin D (84.4% patients in LSG group and 81.3% patients in DJB-SG) and iron (62.5% patients in LSG group and 68.8% patients in DJB-SG) were commonly prevalent nutritional deficiencies at baseline and were significantly reduced at 12 months.

CONCLUSIONS

In the short term, bariatric surgery resulted in weight loss and improvement in glycaemia. Bariatric surgery does significantly affect dietary intake leading to nutritional deficiencies. Therefore, patients should be recommended vitamin and mineral supplements and regular patient education and counselling by a trained bariatric dietitian to prevent nutritional deficiencies and maintain nutritional status.

Diabetes Remission After Bariatric Surgery: A 10-Year Follow-Up Study

INTRODUCTION

Treatment of type 2 diabetes (T2DM) in patients with obesity can be challenging. Metabolic and bariatric surgery (MBS) has shown promising results in improving glycemic control and even achieving remission in T2DM patients with obesity. However, the durability of glycemic improvements in T2DM patients following MBS remains insufficiently studied.

AIM

Determine the incidence of durable remission and relapse of T2DM rates 10 years after MBS, characterize the glycemic profile after surgery, and identify factors predicting persistent remission of T2DM.

METHODS

Retrospective observational study of T2DM patients undergoing MBS between 2010 and 2013. Clinical and analytical assessments were performed preoperatively, at 2- and at 10-years postoperatively. Paired t-tests, Wilcoxon-signed-rank and McNemar tests were used to assess the differences in the metabolic status during the follow-up. Logistic regression models were used to identify predictors of T2DM remission.

RESULTS

Ninety-five patients were included (mean age 48.8 ± 9.1 years, mean HbA1c 7.0 ± 1.5%). Ten years after surgery, the rate of complete T2DM remission was 31%, partial remission was 15%, and late recurrence after initial remission was 24%. Patients with lower HbA1c (OR = 0.50; p = 0.05) and taking fewer antidiabetic drugs (OR = 0.31; p = 0.01) preoperatively were more likely to maintain long-term remission. Ten years post-MBS, patients maintained lower fasting plasma glucose (p < 0.001), HbA1c (p < 0.001), number of antidiabetic drugs (p < 0.001), and insulin use (p < 0.001).

CONCLUSION

MBS can induce a significant improvement and sustainable remission of T2DM. Early intervention, while patients still have a good glycemic control with a lower number of anti-diabetic drugs, is crucial to achieve long-lasting benefits and a potential "surgical cure" for T2DM.

Evaluation of the nutritional status of morbid obesity patients in the first six months after sleeve gastrectomy

Introduction

Objective: in recent years, bariatric surgery has gained popularity as a treatment for obesity worldwide. While patients do experience weight loss after surgery, it is important to be aware that serious nutritional deficiencies may also occur. This study was conducted to evaluate the nutritional status of morbidly obese patients in the first six months after sleeve gastrectomy. Methods: the study was planned as a retrospective study. The data of 76 patients aged 19-64 years who had undergone bariatric surgery and were followed by a dietitian for at least 6 months were included in the study. Preoperative and postoperative biochemical parameters and anthropometric measurements of the patients were taken. Results: the lowest body weight of the patients was found at postoperative month 6 (81.74 ± 14.83 kg), the body weight at the preoperative period (115.86 ± 21.28 kg) and postoperative month 1 (100.39 ± 18.28 kg), and the body weight at postoperative month 1 was statistically lower than at the preoperative period. The preoperative body weights and BMI values of the patients were higher than at postoperative months 1 and 6, and the postoperative month 1 values were higher than at postoperative month 6 (p < 0.05). The lowest fasting blood glucose (83.48 ± 8.44 mg/dL), HbA1c (4.96 ± 0.95 %), and Homa-IR (3.34 ± 0.92) were observed at the postoperative month 6. Compared with the preoperative period, the iron level of the patients increased from 69.54 ± 29.82 µg/dL to 96.52 ± 25.39 µg/dL in postoperative month 6, vitamin D levels from 14.48 ± 8.70 µg/dL to 23.96 ± 4.79 µg/dL. While preoperative blood triglyceride and LDL values were statistically higher than in postoperative months 1 and 6, the HDL value was lower (p < 0.05). Conclusion: as a result, after sleeve gastrectomy, patient body weight decreased, and blood lipid profile and diabetes symptoms improved.

Identification of circulating apolipoprotein M as a new determinant of insulin sensitivity and relationship with adiponectin

BACKGROUND

The adiponectin is one of the rare adipokines down-regulated with obesity and protects against obesity-related disorders. Similarly, the apolipoprotein M (apoM) is expressed in adipocytes and its expression in adipose tissue is associated with metabolic health. We compared circulating apoM with adiponectin regarding their relationship with metabolic parameters and insulin sensitivity and examined their gene expression patterns in adipocytes and in the adipose tissue.

METHODS

Circulating apoM and adiponectin were examined in 169 men with overweight in a cross-sectional study, and 13 patients with obesity during a surgery-induced slimming program. Correlations with clinical parameters including the insulin resistance index (HOMA-IR) were analyzed. Multiple regression analyses were performed on HOMA-IR. The APOM and ADIPOQ gene expression were measured in the adipose tissue from 267 individuals with obesity and a human adipocyte cell line.

RESULTS

Participants with type 2 diabetes had lower circulating adiponectin and apoM, while apoM was higher in individuals with dyslipidemia. Similar to adiponectin, apoM showed negative associations with HOMA-IR and hs-CRP (r < -0.2), and positive correlations with HDL markers (HDL-C and apoA-I, r > 0.3). Unlike adiponectin, apoM was positively associated with LDL markers (LDL-C and apoB100, r < 0.20) and negatively correlated with insulin and age (r < -0.2). The apoM was the sole negative determinant of HOMA-IR in multiple regression models, while adiponectin not contributing significantly. After surgery, the change in HOMA-IR was negatively associated with the change in circulating apoM (r = -0.71), but not with the change in adiponectin. The APOM and ADIPOQ gene expression positively correlated in adipose tissue (r > 0.44) as well as in adipocytes (r > 0.81). In adipocytes, APOM was downregulated by inflammatory factors and upregulated by adiponectin.

CONCLUSIONS

The apoM rises as a new partner of adiponectin regarding insulin sensitivity. At the adipose tissue level, the adiponectin may be supported by apoM to promote a healthy adipose tissue.

TRIAL REGISTRATION

NCT01277068, registered 13 January 2011; NCT02332434, registered 5 January 2015; and NCT00390637, registered 20 October 2006.

Challenges of Revisional Metabolic and Bariatric Surgery: A Comprehensive Guide to Unraveling the Complexities and Solutions of Revisional Bariatric Procedures

Revisional metabolic and bariatric surgery (RMBS) presents unique challenges in addressing weight loss failure or complications arising from initial bariatric procedures. This review aims to explore the complexities and solutions associated with revisional bariatric procedures comprehensively, offering insights into the evolving terrain of metabolic and bariatric surgery. A literature review is conducted to identify pertinent studies and expert opinions regarding RMBS. Methodological approaches, patient selection criteria, surgical techniques, preoperative assessments, and postoperative management strategies are synthesized to provide a comprehensive overview of current practices and advancements in the field, including institutional protocols. This review synthesizes key findings regarding the challenges encountered in RMBS, including the underlying causes of primary procedure failure, anatomical complexities, technical considerations, and assessments of surgical outcomes. Additionally, patient outcomes, complication rates, and long-term success are presented, along with institutional approaches to patient assessment and procedure selection. This review provides valuable insights for clinicians grappling with the complexities of RMBS. A comprehensive understanding of patient selection, surgical techniques, preoperative management, and postoperative care is crucial for enhancing outcomes and ensuring patient satisfaction in the field of metabolic bariatric surgery.

Cardiometabolic Improvements After Metabolic Surgery and Related Presurgery Factors

Context

Metabolic surgery remains the most effective and durable treatment for severe obesity and related metabolic diseases.

Objective

We examined cardiometabolic improvements after metabolic surgery and associated presurgery demographic and clinical factors in a large multiracial cohort.

Methods

Included were 7804 patients (20-79 years) undergoing first-time metabolic surgery at Vanderbilt University Medical Center from 1999 to 2022. Pre- and 1-year postsurgery cardiometabolic profiles were extracted from medical records, including body mass index (BMI), blood pressure, blood lipids, glucose, and hemoglobin A1c. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk was estimated per American College of Cardiology/American Heart Association equations. Pre- to postsurgery cardiometabolic profiles were compared by paired t-test, and associated factors were identified by multivariable linear and logistic regression.

Results

Among 7804 patients, most were women and White, while 1618 were men and 1271 were Black; median age and BMI were 45 years [interquartile range (IQR): 37-53] and 46.4 kg/m2 (IQR: 42.1-52.4). At 1-year postsurgery, patients showed significant decreases in systolic blood pressure (10.5 [95% confidence interval: 10.1, 10.9] mmHg), total cholesterol (13.5 [10.3, 16.7] mg/dL), glucose (13.6 [12.9, 14.4] mg/dL), hemoglobin A1c (1.13% [1.06, 1.20]), and 10-year ASCVD risk (absolute reduction: 1.58% [1.22, 1.94]; relative reduction: 34.4% [29.4, 39.3]); all P < .0001. Older, male, or Black patients showed less reduction in 10-year ASCVD risk and lower odds of diabetes/hypertension/dyslipidemia remission than younger, female, or White patients. Patients with a history of diabetes, hypertension, dyslipidemia, or cardiovascular disease showed less cardiometabolic improvements than those without. Results were similar with or without further adjusting for weight loss and largely sustained at 2-year postsurgery.

Conclusion

Metabolic surgery results in significant cardiometabolic improvements, particularly among younger, female, or White patients and those without comorbidities.

Hypertension and hypercholesterolemia are predictive factors associated with type 2 diabetes persistence after metabolic surgery: A prospective study

BACKGROUND

Metabolic surgery is the most effective therapeutic strategy for the management of type 2 diabetes (T2DM). Several preoperative clinical factors have been associated with T2DM remission after metabolic surgery. However, other potential predictors remain unexplored.

AIM

To assess the role of basal (pre-surgery) clinical and biochemical parameters in T2DM remission after metabolic surgery.

METHODS

A prospective study including 98 patients with T2DM undergoing metabolic surgery was performed. Clinical, anthropometric, and biochemical data were collected at baseline and 1 year following metabolic surgery.

RESULTS

Patients without T2DM remission 1 year after metabolic surgery presented a longer duration of diabetes and higher glycated hemoglobin (HbA1c) levels; a higher percentage of these subjects were using insulin therapy, antihypertensive drugs, and lipid-lowering therapies before metabolic surgery, compared to those patients with T2DM remission. A lower percentage of T2DM remission after metabolic surgery was observed among patients with hypertension/hypercholesterolemia before surgery, compared to those patients without hypertension/hypercholesterolemia (51.7 % vs 86.8 %, p < 0.001, and 38.5 % vs 75 %, p < 0.001, respectively), and among patients with longer duration of diabetes (≥5 years vs <5 years; 44.4 % vs 83 %, respectively; p < 0.001). In the logistic regression model, diabetes duration, basal HbA1c, and the presence of hypertension and hypercholesterolemia before surgery were inversely related to T2DM remission following metabolic surgery, after adjusting for sex, age, waist circumference, and type of surgery.

CONCLUSIONS

In a cohort of patients with obesity and T2DM, preoperative hypertension and hypercholesterolemia, together with a longer diabetes duration and higher HbA1c concentrations, were independent predictors of T2DM persistence after metabolic surgery.

Association of Baseline Triglyceride-Glucose Index with Poor Glycemic Control and Diabetes Remission After Metabolic Surgery

PURPOSE

The utility of insulin resistance (IR) as a predictor of diabetes remission after metabolic surgery is not well-defined. We assessed the association of baseline surrogate IR indices including triglyceride-glucose (TyG) index and homeostatic model assessment for IR (HOMA-IR) with glycemic control and diabetes remission after metabolic surgery.

MATERIALS AND METHODS

Patients with type 2 diabetes scheduled for metabolic surgery were recruited at a single-center (n = 149; age: 44 ± 10 years, 47.7% men, body mass index: 41.5 ± 7.5 kg/m²), and followed-up for 12 months postoperatively. The relationships between the IR indices and poor glycemic control (HbA1c ≥ 7%) at baseline or complete diabetes remission (HbA1c < 6% without glucose-lowering medications at 12 months) post-surgery were examined.

RESULTS

Elevated TyG index was associated with poor glycemic control cross-sectionally. Compared with non-remitters, lower baseline TyG index levels were observed in individuals with complete diabetes remission after surgery (P = 0.012); whereas HOMA-IR was not significantly different. Consistently, the proportion of diabetes non-remitters (compared to remitters) increased with increasing TyG tertiles from 1 to 3 (P = 0.015). Both TyG index (relative risk = 0.62, 95% CI = 0.42-0.91, P = 0.014) and TyG tertile 1 (relative risk = 1.99, 95% CI = 1.25-3.24, P = 0.003) independently predicted diabetes remission. The TyG index identified diabetes remission with an area under the curve of 0.68. The optimal TyG threshold was 9.41, yielding a sensitivity of 69.6%, specificity of 60.9%, positive predictive value of 64.0%, and negative predictive value of 66.7%.

CONCLUSION

TyG index, previously suggested to predominantly reflect muscle IR, outperforms HOMA-IR as an IR indicator associated with glycemic control and diabetes remission after metabolic surgery.

Global trends in research related to sleeve gastrectomy: A bibliometric and visualized study

BACKGROUND

One of the most popular bariatric procedures is sleeve gastrectomy, and it has become significantly more common in recent years.

AIM

To evaluate the research activity in sleeve gastrectomy over the last two decades, and to visualize the hot spots and emerging trends in this type of bariatric surgery using bibliometric methods.

METHODS

The Scopus database was used to search for publications related to sleeve gastrectomy. The retrieved publications were reviewed in terms of year of publication, type of study, country of origin, institutions, journals, and citation patterns by using descriptive analysis. Collaboration network and term co-occurrence analysis were visualized by using VOSviewer software.

RESULTS

The search strategy yielded a total of 6508 publications on sleeve gastrectomy from 2001 to 2020. As regards the document type, the majority were articles (n = 5230; 80.36%), followed by reviews (n = 544; 8.36%). The top three countries are the United States, with 1983 publications (30.47%), followed by France (600; 9.22%) and Italy (417; 6.71%). The most cited publication was published in 2012 by Schauer et al in the New England Journal of Medicine (n = 1435 citations). This publication found that weight loss was greater in the sleeve gastrectomy group than in the medical therapy group. Furthermore, this study demonstrated that 12 mo of medical therapy plus bariatric surgery greatly improved glycemic regulation in obese patients with uncontrolled type 2 diabetes compared with medical therapy alone. The focus of the current literature on sleeve gastrectomy was directed toward several themes such as morbidity and potential complications, the complexity of the procedure and different surgical approaches, and diabetes and body mass index in correlation to sleeve gastrectomy.

CONCLUSION

The number of sleeve gastrectomy publications has gradually grown over the last 20 years. This bibliometric analysis could help researchers better understand the knowledge base and research frontiers surrounding sleeve gastrectomy. In addition, future studies may focus on emerging research hotspots.

Bariatric Surgery in Cebu, Philippines: Current Status and Initial Experience With Laparoscopic Sleeve Gastrectomy

Background The prevalence of obesity in the Philippines has increased more than three-fold over the last two decades. However, bariatric surgery has not been widely adopted yet in the country. Local data mainly on laparoscopic adjustable gastric banding (LAGB) and Roux-en-Y gastric bypass (RYGB) are limited as well. We report for the first time our experience with laparoscopic sleeve gastrectomy (LSG) and present the current local status of bariatric surgery in Cebu, Philippines. Patients and methods This is a retrospective study of all patients 18 years old and above who underwent LSG in a single, private, tertiary institution during the period 2009 - 2019. Our primary endpoint was weight loss after LSG. Secondary endpoint was postoperative complications. Results Thirty-three patients (mean age 40.9 ± 14.5 years) underwent LSG. Baseline weight and BMI were 112.6 ± 29 kg and 41.3 ± 8.6, respectively. The mean operative duration was 201 ± 72.9 minutes. The were no open conversions with minimal morbidity. Mean hospital stay was 3.7 ± 0.9 days. The postoperative mean weight and BMI after one year were 68.9 ± 17 kg and 26.6 ± 6, respectively. Overall, mean excess weight loss (EWL) was 61.9 ± 44.1 % at a median follow-up of 5.4 months. Significant weight loss was noted after the third month. Conclusion  LSG is a safe and effective method in producing weight loss. It can be a definitive treatment option as local prevalence of obesity is increasing in the Philippines. However, access to and the practice of bariatric surgery remains limited in the country. A collaboration among private and government stakeholders is essential.